

**RECEIVED**  
**CENTRAL FAX CENTER**  
**OCT 27 2004**

Attorney Docket No.: 5367.230-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Knudsen et al

Serial No.: 10/730,215

Group Art Unit: 1636

Filed: December 8, 2003

Examiner: McKelvey, Terry Alan

For: GLP-2 Derivatives

**CERTIFICATE OF FACSIMILE TRANSMISSION**  
**703-872-9306**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner McKelvey, Terry Alan, fax number (703) 872-9306.

Respectfully submitted,

Date: October 27, 2004

  
Csaba Attila Szokolczai  
Novo Nordisk® Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**RECEIVED**  
**CENTRAL FAX CENTER**

**OCT 27 2004**

**PATENT**

Attorney Docket No. 5367.230-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Knudsen et al.

Application No. 10/730,215

Filed: December 8, 2003

For: GLP-2 DERIVATIVES

Group Art Unit: 1636

Examiner: McKelvey, Terry Alan

**AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Prior to further consideration of the above-referenced patent application, please amend the application and consider the provided remarks as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the **Listing of Claims**, which begins on page 7 of this paper.

**Remarks** concerning the amendments begin on page 10 of this paper.